Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination With Nivolumab In Patients With Advanced Solid Tumors
NCT Number:
NCT03504488
Phase:
I/II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lung
Study Objectives:
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Study Documents
(MUSC NetID required for document access)